Servier, Institut Curie deal

Servier and the institute's Curie-Cancer unit extended by three years to 2017 their 2005 deal to identify targets to treat triple-negative breast cancer. The partners co-own the IP and the institute is eligible for royalties on products developed under the deal. ...